| NCT05907447
| A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | No drug interventions | Not Available | Not Available | not_yet_recruiting |
| NCT04480788
| CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | No drug interventions | treatment | 1 | unknown_status |
| NCT04096690
| Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT01667302
| Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT04639843
| Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | No drug interventions | treatment | 1 | withdrawn |
| NCT03493451
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | | treatment | 2 | completed |
| NCT00901147
| Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | | treatment | 2 | completed |
| NCT03999658
| A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies | | treatment | 2 | withdrawn |
| NCT02733458
| GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma | | treatment | Not Available | completed |
| NCT04414163
| A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | | treatment | 2 | active_not_recruiting |
| NCT02631239
| MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma | | treatment | 3 | unknown_status |
| NCT04602065
| Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial | No drug interventions | treatment | 1 / 2 | terminated |
| NCT02229682
| Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy | No drug interventions | treatment | 2 | unknown_status |
| NCT02742727
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | | treatment | 1 / 2 | unknown_status |
| NCT04676789
| Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL | No drug interventions | treatment | 2 | not_yet_recruiting |
| NCT01667289
| Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | No drug interventions | treatment | 2 | terminated |
| NCT03079544
| Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients | No drug interventions | Not Available | Not Available | completed |
| NCT02764281
| MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma | No drug interventions | treatment | Not Available | completed |
| NCT01921790
| Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT02825147
| Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma | No drug interventions | treatment | 2 | completed |
| NCT01787409
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | No drug interventions | treatment | Not Available | recruiting |
| NCT02652715
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | No drug interventions | basic_science | Not Available | completed |
| NCT04405375
| GPED Regimen for Relapsed/Refractory or Advanced ENKTCL | No drug interventions | treatment | 2 | unknown_status |
| NCT02386813
| International Extranodal NK/T-cell Lymphoma Project | No drug interventions | Not Available | Not Available | completed |
| NCT05978141
| A Registry for People With T-cell Lymphoma | No drug interventions | Not Available | Not Available | recruiting |
| NCT01991158
| GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT05475925
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | No drug interventions | treatment | 1 / 2 | recruiting |
| NCT04509466
| Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL | No drug interventions | treatment | 1 / 2 | terminated |
| NCT04338282
| Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT03363555
| SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT01238159
| Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma | No drug interventions | treatment | 2 | completed |
| NCT02085655
| PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | No drug interventions | treatment | 3 | unknown_status |
| NCT05149170
| Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL | No drug interventions | treatment | 2 | recruiting |
| NCT05254899
| Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL | No drug interventions | treatment | 2 | recruiting |
| NCT04952584
| Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas | No drug interventions | treatment | 1 | withdrawn |
| NCT02560441
| Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type | No drug interventions | treatment | 2 | unknown_status |
| NCT04288726
| Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | No drug interventions | treatment | 1 | recruiting |
| NCT01501149
| Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ | No drug interventions | treatment | 4 | unknown_status |
| NCT01501136
| Treatment of Natural Killer/T Cell Lymphoma-I/II | No drug interventions | treatment | 4 | unknown_status |
| NCT03623087
| SIMPLE Chemotherapy for NK Lymphoma/Leukaemia | | treatment | 3 | unknown_status |
| NCT06583083
| Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma | | treatment | 2 | recruiting |
| NCT04366128
| Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL | No drug interventions | treatment | Not Available | unknown_status |
| NCT04004572
| Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT03618238
| Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma | No drug interventions | treatment | 2 | completed |
| NCT06376721
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | No drug interventions | treatment | 1 / 2 | recruiting |
| NCT03936452
| Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma | No drug interventions | treatment | 2 | completed |
| NCT06314334
| Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma | No drug interventions | treatment | 2 | recruiting |
| NCT03630731
| Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT03107962
| Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma | No drug interventions | treatment | 2 | unknown_status |
| NCT05058755
| Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma | No drug interventions | treatment | Not Available | completed |